1. Introduction {#sec1-biomedicines-07-00060}
===============

A menopausal hot flush (MHF) is a sudden and transient onset of erythema and warmth or burning sensation on the face and skin of the neck which appears during the transition to (pre-menopausal and peri-menopausal), and through, menopause (menopausal and post-menopausal) \[[@B1-biomedicines-07-00060],[@B2-biomedicines-07-00060]\]. The onset commonly lasts for seconds to five minutes, but its persistence duration is unpredictable \[[@B3-biomedicines-07-00060]\]. MHFs significantly impact the quality of life of both the sufferers and their families \[[@B3-biomedicines-07-00060]\]. Its mechanism has not been fully investigated. The sudden reduction in estrogen level, the narrowed central thermoneutral zone, changes of the certain neurotransmitter synthesis (e.g., noradrenaline and serotonin), and peripheral vascular reactivity are linked to MHF onset \[[@B4-biomedicines-07-00060],[@B5-biomedicines-07-00060],[@B6-biomedicines-07-00060],[@B7-biomedicines-07-00060],[@B8-biomedicines-07-00060],[@B9-biomedicines-07-00060]\]. Menopausal hormone therapy is the most popular and effective MHF management \[[@B10-biomedicines-07-00060],[@B11-biomedicines-07-00060]\]. However, adverse effects, such as nausea, dizziness, dry mouth, and contraindication, with hormone-dependent diseases (e.g., breast cancer) exist \[[@B12-biomedicines-07-00060]\]. Thus, more than half of all middle-aged menopausal women have taken non-hormonal therapies \[[@B13-biomedicines-07-00060]\], such as Chinese herbal medicine (CHM).

Guizhi Fuling Wan (GFW, also known as Keishibukuryogan) is a classic Chinese herbal formula that has been used for MHFs in modern clinical practice \[[@B14-biomedicines-07-00060],[@B15-biomedicines-07-00060]\]. In ancient China, there was no specific terminology used for MHFs. One Classic book, Ying Er Lun (Treatise on Infants), advocated that GFW could be used to treat flushed complexion in females of which the description is similar to MHF symptoms. As recorded in Jin Gui Yao Lue Fang Lun (Synopsis of Prescriptions of the Golden Chamber) \[[@B16-biomedicines-07-00060]\], GFW consists of five herbal ingredients, including Gui Zhi (Cinnamomi Ramulus), Shao Yao (Paeoniae Radix Alba or Paeoniae Radix Rubra), Mu Dan Pi (Moutan Cortex), Tao Ren (Persicae Semen), and Fu Ling (Poria) \[[@B16-biomedicines-07-00060]\]. The 2015 edition of the Chinese Pharmacopeia indicates that Bai Shao (Paeoniae Radix Alba) is used in tablet and capsule form GFW, whereas Chi Shao (Paeoniae Radix Rubra) is used in honey pill form \[[@B17-biomedicines-07-00060]\]. In 2006, a GFW product (capsule) was approved by the US Food and Drug Administration to enter Phase II clinical trials \[[@B18-biomedicines-07-00060]\]. Recently, more experimental studies have been conducted to investigate the pharmacodynamic effects of GFW \[[@B19-biomedicines-07-00060],[@B20-biomedicines-07-00060],[@B21-biomedicines-07-00060]\]. However, GFW's application and mechanisms of actions on MHFs have not been systematically reviewed. This paper investigated the therapeutic effects of GFW on the management of MHFs from clinical and experimental perspectives.

2. Clinical Application of GFW on MHFs {#sec2-biomedicines-07-00060}
======================================

The formula name and its synonyms were searched as keywords in 20 electronic databases (Cochrane Library, PubMed, EMBASE, AMED, CINAHL, Informit, Science Direct, LILACS, ProQuest, Wiley Online Library, PsycINFO, IndMED, AcuBriefs, Ingenta, KoreaMed, ERIC, CNKI, CQVIP, Wanfang Data, and sinoMed) for English or Chinese language papers from the earliest records available in each database, up to April 2019. The reference lists of articles with relevant topics were manually screened to identify potentially relevant studies. After removal of duplicates, the titles and abstracts of identified potential studies were screened. Full-texts were obtained for eligibility assessment against the selection criteria. All types of clinical studies (including randomized controlled trials (RCTs), non-randomized parallel controlled studies, and case series) were considered for inclusion as long as they recruited patients with MHFs or used MHFs as one of the outcome measures. To ensure comparability of the intervention, only studies using GFW in non-modified forms (e.g., decoction, pills, granules, and capsules with acceptable variations of Bai Shao/Chi Shao/Shao Yao) were considered. For studies involving control groups, only those that compared GFW with placebo, no treatment, or conventional medicine were considered. Studies utilizing any co-interventions were excluded.

A predesigned form was used to record extracted data, including study design, setting, sample size, the age, and diagnosis of the participants, intervention, duration, and outcome measures (including frequency and severity of MHFs, level of hormones/cytokines, and peripheral blood flow). Corresponding authors of potential articles were contacted by email, Research Gate ([www.researchgate.net](www.researchgate.net)), and LinkedIn ([www.linkedin.com](www.linkedin.com)) for missing data. Replies with unpublished data were received from corresponding authors of two papers \[[@B22-biomedicines-07-00060],[@B23-biomedicines-07-00060]\]. The quality of included studies was analyzed according to study types. For RCTs, the quality was assessed using Cochrane's risk of bias assessment tool \[[@B24-biomedicines-07-00060]\] with focus on the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). Quality was categorized as "Low risk", "Unclear risk", and "High risk" of bias. The quality of parallel controlled studies was evaluated by ROBINS-I ("Risk Of Bias In Non-randomised Studies - of Interventions") \[[@B25-biomedicines-07-00060]\], and the assessed domains included confounding, participant selection, intervention classification, deviations from intended interventions, missing data, outcome measurement, and reported results. Quality was classified as "Low risk", "Moderate risk", "Serious risk", and "Critical risk" of bias. The quality of case series was assessed in four domains according to the Instrument for Evaluating the Quality of case series in CHM, including study aims and design (two questions), descriptions of treatment protocol (three questions), descriptions of methods and therapeutic/side-effects (two questions), and conduct of the study (six questions) \[[@B26-biomedicines-07-00060]\]. A score of "1" was given when 'Yes' was applied to one item. Any article with a total score ≥ 7 was considered to have good quality.

A total of 12988 records were identified, and seven of them met the inclusion criteria. [Figure 1](#biomedicines-07-00060-f001){ref-type="fig"} illustrates the selection process of the included studies. Two RCTs \[[@B14-biomedicines-07-00060],[@B15-biomedicines-07-00060]\], one parallel controlled study \[[@B27-biomedicines-07-00060]\], and two case series \[[@B28-biomedicines-07-00060],[@B29-biomedicines-07-00060]\] were included in this review. Another two studies \[[@B22-biomedicines-07-00060],[@B23-biomedicines-07-00060]\] were claimed as controlled trials; however, two intervention groups were incomparable. Thus, the treatment groups of these two studies were considered as case series studies, and only data from GFW groups were extracted for analyses in this review. The characteristics of the included studies are summarized in [Table 1](#biomedicines-07-00060-t001){ref-type="table"}.

2.1. RCTs {#sec2dot1-biomedicines-07-00060}
---------

One RCT \[[@B15-biomedicines-07-00060]\] reported that both low dosage (7.5 g/day) and high dosage (12.5 g/day) GFW could significantly reduce MHF frequency and severity when comparing between before and after the 12-week intervention. When compared to placebo, there was no statistical significance. However, the reduction may be dose-dependent, as the results from the high dosage group demonstrated a greater reduction, which provided a direction for future research on the relationship between GFW dosage and clinical effects. Another RCT \[[@B14-biomedicines-07-00060]\] reported that the peripheral blood flow in postmenopausal females with MHFs in the GFW group (*n* = 67) was significantly decreased compared to the menopausal hormone therapy group (*n* = 64) under the jaw (mean difference (MD) --3.56, 95% confidence interval (CI) --5.17 to --1.95) and in the middle fingertip (MD --7.10, 95% CI --10.99 to --3.21) at the end of one-month treatment. Opposite effects on the blood flow in the third toe were observed in two groups: GFW increased the blood flow in the toe, whereas menopausal hormone therapy caused a decrease.

2.2. Parallel Controlled Study {#sec2dot2-biomedicines-07-00060}
------------------------------

The parallel controlled study \[[@B27-biomedicines-07-00060]\] reported positive results, concluding that the severity of MHFs in 73.7% of the participants improved from severe to mild or moderate after six-month GFW intake. It was significantly higher than the control group. No significant difference in estradiol (E~2~) and follicle-stimulating hormone (FSH) levels was observed between groups. Results of serum cytokine level indicated that serum monocyte chemotactic protein-1 (MCP-1) level in women treated with keishibukuryogan decreased significantly (--16.3%) compared to the no treatment group (3.8%). Further analysis of the GFW responder group (*n* = 28) indicated that concentrations of serum interleukin (IL)-8 and macrophage inflammatory protein (MIP)-1β were reduced significantly, whereas those in the non-responders were increased dramatically. Sub analysis results on menopausal transition status showed that GFW decreased the IL-8 and MIP-1β levels in perimenopausal GFW responders and MCP-1 in postmenopausal GFW responders.

2.3. Case Series {#sec2dot3-biomedicines-07-00060}
----------------

One case series study \[[@B29-biomedicines-07-00060]\] revealed that the improvement of MHF severity was related to genetic variation of the polymorphic dinucleotide (CA) repeat of the estrogen receptor beta (ESR2) gene on chromosome 14, which include three types: two short alleles (SS), two long alleles (LL), and a short and long allele (SL) \[[@B30-biomedicines-07-00060],[@B31-biomedicines-07-00060]\]. MHF severity in participants with LL genotype improved significantly after the intervention. FSH level changes also depended on genotype: FSH levels decreased in participants with SS genotype but increased in participants with SL or LL genotypes. E~2~ level decreased in all genotype groups. Another case series \[[@B28-biomedicines-07-00060]\] reported that the plasma calcitonin gene-related peptide (CGRP) level in eight post-menopausal participants significantly decreased after the four-week GFW intervention when compared to baseline data (MD --2.88, 95% Cl --4.07 to --1.69). CGRP is a potent vasodilator neuropeptide, and it is hypothesized to be a specific vasodilation neuropeptide of MHFs, which significantly rose in concentration during MHF onset \[[@B32-biomedicines-07-00060]\]. However, GFW's effects on changes of frequency before and after intervention in three case series had no statistically significant difference (standardized mean difference (SMD) --1.15, 95% CI --2.49 to 0.20) \[[@B22-biomedicines-07-00060],[@B23-biomedicines-07-00060],[@B28-biomedicines-07-00060]\].

3. Experimental Studies on Phytochemistry and Pharmacodynamics of GFW on MHFs {#sec3-biomedicines-07-00060}
=============================================================================

We searched the 20 English and Chinese databases, detailed in [Section 2](#sec2-biomedicines-07-00060){ref-type="sec"}, to identify experimental studies that have investigated the chemical compounds of GFW. Studies were excluded if they did not provide the following details: (1) plants with valid plant specimen voucher numbers, ingredients and ratios for raw herbs (decoction), or (2) company names and batch/lot numbers for purchased patent products (pills, granules, or capsules).

For pharmacodynamics, the same set of 20 databases was searched to identify experimental studies that have investigated GFW on MHFs. To be eligible to be included, the studies must provide the details as specified in (1) and (2) as above. Also, experiments were required to have (3) utilized cell or animal models related to MHFs; (4) compared GFW's effects with the blank model control group (i.e., no treatment); (5) evaluated the pharmacodynamic effects on MHFs. Studies involving any co-interventions were excluded.

The structures of chemical compounds were drawn using BIOVIA Draw 2019 \[[@B33-biomedicines-07-00060]\] or Avogadro \[[@B34-biomedicines-07-00060]\]/Discovery Studio Visualizer 2019 \[[@B35-biomedicines-07-00060]\]. Molecular weight was calculated by Lenntech Molecular Weight Calculator (<https://www.lenntech.com/calculators/molecular/molecular-weight-calculator.htm>). The quality of in vivo studies was assessed based on 20 domains specified in the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines \[[@B36-biomedicines-07-00060]\].

As a result, 35 studies on phytochemistry, and four studies on pharmacodynamics met the inclusion criteria. [Figure 1](#biomedicines-07-00060-f001){ref-type="fig"} illustrates the selection process of the included studies.

3.1. Phytochemistry of GFW {#sec3dot1-biomedicines-07-00060}
--------------------------

The included studies on phytochemicals from GFW reported 169 compounds: four from Cinnamomi Ramulus (A1 and B1--B3), 13 from Persicae Semen (A1 and C1--C12), 41 from Moutan Cortex (A1, D1--D20, and E1--E20), 31 from Paeoniae Radix (A1, D1--D20, and F1--F10), 31 from Poria (A1 and G1--G30), 44 without clearly defined resources (H1--H44), and 29 inorganic elements. [Table 2](#biomedicines-07-00060-t002){ref-type="table"} outlines the characteristics of chemical constituents isolated from GFW. The molecular structures of 144 phytochemicals could be identified with their corresponding PubChem CIDs (compound identification number)/SIDs (substance identification number), whereas 25 constituents were not available in the PubChem database. Among those 25 chemical components, structures of 23 phytochemicals (C3, C6, D1, D6, D10, D12, D13, D14, D19, D20, E1, E10, F1, F2, F7, G4, G5, G12, G14, G21, H1, H2, H15) were provided in the included studies. One compound structure (G10) was available in a reference paper (as cited in [Table 2](#biomedicines-07-00060-t002){ref-type="table"}), whereas one (G11) could not be found in any known data source. Details of the 24 molecular structures are presented in [Figure 2](#biomedicines-07-00060-f002){ref-type="fig"}.

The latest standards for different GFW forms established by high-performance liquid chromatography (HPLC) to guarantee the quality of GFW were cinnamic acid (B2) ≥72 µg and paeonol (E14) ≥6 mg per pill in honey pill form; paeonol (E14) ≥1.8 mg, paeoniflorin (F9) ≥3 mg, and amygdalin (C2) ≥1.5 mg per tablet in tablet form; paeonol (E14) ≥1.8 mg, paeoniflorin (F9) ≥3 mg, and amygdalin (C2) ≥ 0.9 mg per capsule in capsule form \[[@B17-biomedicines-07-00060]\].

3.2. Pharmacodynamic Effects of GFW on MHFs {#sec3dot2-biomedicines-07-00060}
-------------------------------------------

Characteristics and results of included in vivo studies are summarized in [Table 3](#biomedicines-07-00060-t003){ref-type="table"}. The results from the quality assessment of included in vivo experimental studies are presented in [Figure 3](#biomedicines-07-00060-f003){ref-type="fig"}. The results suggested that GFW had a similar action to E~2~ on managing skin temperature by restoring the plasma level of CGRP: it increased the ovariectomy-induced CGRP reduction \[[@B66-biomedicines-07-00060],[@B67-biomedicines-07-00060]\] and reduced CGRP-induced elevation of skin temperature in GnRH (gonadotropin-releasing hormone) analog-treated rats \[[@B67-biomedicines-07-00060],[@B68-biomedicines-07-00060]\]. A dose-dependent skin temperature change was detected, showing that a significant inhibition effect on elevated skin temperature was observed at a dose of 1000 mg/kg \[[@B67-biomedicines-07-00060],[@B68-biomedicines-07-00060]\]. However, GFW had no significant effects on CGRP concentrations and CGRP mRNA levels in the dorsal root ganglia \[[@B66-biomedicines-07-00060]\], which suggested minor effects on CGRP synthesis in an ovariectomized rat model. GFW had no significant effects on CGRP concentrations in the spinal cord \[[@B66-biomedicines-07-00060]\], which suggested that it may have an inconsequential influence on CGRP's effects on the central nervous system in the ovariectomized rat model.

One in vitro experimental study \[[@B69-biomedicines-07-00060]\] utilized an ESR-dependent cell proliferation bioassay and an ESR-dependent reporter assay to investigate the potential estrogenic activity of GFW and its metabolites. The results demonstrated that GFW showed no estrogenic activity and low ER β-dependent estrogenic activity before or after metabolization with a concentration at 100 μg/mL. Findings from two in vivo studies concluded that E~2~ could significantly reduce the levels of pituitary LH (luteinizing hormone) and FSH, as well as the weights of uterus and ovaries, whereas GFW did not influence those factors \[[@B67-biomedicines-07-00060],[@B68-biomedicines-07-00060]\]. Thus, GFW did not confer estrogen activity on plasma and might exert pharmacodynamic effects against MHFs via other pathways.

4. Translation from Experimental Studies to Clinical Practice {#sec4-biomedicines-07-00060}
=============================================================

4.1. Therapeutic Effects {#sec4dot1-biomedicines-07-00060}
------------------------

A well-designed RCT is considered as the gold standard when evaluating the effects of an intervention \[[@B70-biomedicines-07-00060]\]. However, its limitations have triggered extensive discussion as RCTs may be unnecessary, inappropriate, inadequate, or even impossible in the clinic, and methodological problems can cause bias in the results \[[@B71-biomedicines-07-00060],[@B72-biomedicines-07-00060],[@B73-biomedicines-07-00060]\]. Besides, CHM involves a holistic therapeutic approach. However, most of the published RCTs on CHM were designed to only investigate the therapeutic aspects (i.e., Chinese medicine intervention + western medicine diagnosis) instead of the holistic therapeutic approach (i.e., Chinese medicine intervention + Chinese medicine diagnosis) \[[@B74-biomedicines-07-00060]\]. The importance of integration of various study designs was highlighted to accommodate the evaluation of various research questions and for the outcome of interest \[[@B75-biomedicines-07-00060],[@B76-biomedicines-07-00060]\]. Therefore, the therapeutic effects of a range of study designs were systematically reviewed ([Figure 4](#biomedicines-07-00060-f004){ref-type="fig"}).

As shown in [Figure 4](#biomedicines-07-00060-f004){ref-type="fig"}, the study types and outcome measures varied across all the included studies. Most outcomes were measured in different study designs. GFW demonstrated overall no statistically significant changes in the frequency and severity of MHFs between before and after treatment and no statistically significant differences between GFW and control groups. However, dose-dependent skin temperature changes were detected in both clinical \[[@B15-biomedicines-07-00060]\] and experimental studies \[[@B69-biomedicines-07-00060],[@B70-biomedicines-07-00060]\]. The effective dose suggested in the in vivo study was 1000 mg/kg \[[@B69-biomedicines-07-00060],[@B70-biomedicines-07-00060]\], which was four times the dose in the RCT (12.5 g/day) when the participant weighed in at 50 kg \[[@B15-biomedicines-07-00060]\]. Thus, more dose variation should be considered in further RCTs. The influence of GFW on FSH and E~2~ was unclear based on the included studies due to the limitation of study design. Results of experimental studies indicated that GFW had no effects on LH, FSH, and E~2~ in Sprague-Dawley rats and no estrogenic effects on the rat liver S9 fraction. However, case series studies pointed out that GFW might target a specific human ESR2 beta genotype. GFW was found to affect CGRP level in both case series and in vivo studies \[[@B28-biomedicines-07-00060],[@B66-biomedicines-07-00060],[@B67-biomedicines-07-00060],[@B69-biomedicines-07-00060]\]. GFW had similar effects to E~2~ on normalizing CGRP level but without affecting its synthesis in the dorsal root ganglia. Only peripheral blood flow and cytokines were reported in one study design, which should be further investigated in various studies.

4.2. Potential Multi-Targeting Actions {#sec4dot2-biomedicines-07-00060}
--------------------------------------

Three potential target proteins/cytokine could be proposed based on findings from the above-mentioned clinical and experimental studies: estrogen beta receptor, IL-8, and CGRP receptor.

There are significant associations between the ESR2 CA dinucleotide repeat length and other menopausal-related symptoms. For example, low bone mineral density has been reported previously in pre- and post-menopausal women \[[@B31-biomedicines-07-00060],[@B77-biomedicines-07-00060],[@B78-biomedicines-07-00060]\]. This genetic variation was characterized by Tsukamoto and co-workers in 1998 \[[@B79-biomedicines-07-00060]\]. Recently, ESR2 CA dinucleotide repeat length was reported to be closely related to clinical effects of GFW on MHFs and that it had better performance on participants with the LL genotype \[[@B29-biomedicines-07-00060]\]. Women with the SS genotype had significantly higher values of circulation estrone concentration (highest) when compared to those harboring the LL genotype (lowest) after adjustment for other confounding factors, including age, hormone replacement status, and circulating levels of sex hormone-binding globulin \[[@B31-biomedicines-07-00060]\]. Thus, genetic variation should be considered as an essential factor of using GFW for MHFs to achieve precision treatment. The prevalence of the SS and SL genotypes was approximately 47.79% (108/226) and 22.56% (51/226), respectively \[[@B31-biomedicines-07-00060]\]. The sum of these two genotypes was much higher than that of the LL genotype (29.65%, 67/226). Thus, patients without targeting genotype might contribute to the negative results in the RCT. It is suggested that future research focus on the three genotypes of ESR2 for precision medicine.

IL-8, also known as CXCL8, is a cytokine potentially involved in thermoregulation and was detected to be higher in premenopausal and menopausal women with MHFs than in those without MHFs \[[@B80-biomedicines-07-00060],[@B81-biomedicines-07-00060]\]. GFW could significantly reduce concentrations of serum IL-8, whereas those in the non-responders were increased dramatically \[[@B27-biomedicines-07-00060]\]. Thus, GFW might selectively influence the synthesis of IL-8. However, the underlying mechanism of this selective effect in different MHF sufferers is not fully understood.

CGRP is a widely expressed sensory neuropeptide, which plays a major role in modulating metabolism, inflammatory response, and blood pressure, as well as contributing to nerve development and function \[[@B82-biomedicines-07-00060],[@B83-biomedicines-07-00060],[@B84-biomedicines-07-00060],[@B85-biomedicines-07-00060],[@B86-biomedicines-07-00060]\]. In the sympathetic nervous system, CGRP is believed to be the specific vasodilator responsible for MHFs \[[@B4-biomedicines-07-00060],[@B84-biomedicines-07-00060]\]. Recently, Liang et al. \[[@B86-biomedicines-07-00060]\] have determined the structure of the human CGRP receptor in complex with CGRP, with the Gs-protein heterotrimer at 3.3 Å global resolution, which makes it possible for future investigation of the potential herb-target relationship between GFW and MHF-related target protein.

4.3. Safety {#sec4dot3-biomedicines-07-00060}
-----------

Inorganic elements that may have vital biological activities in the human body were traced in GFW, including calcium, sodium, magnesium with a dose over 300 µg/g, followed by iron, manganese, and strontium with a dose over 10 µg/g \[[@B65-biomedicines-07-00060]\]. The dosage of toxic inorganic elements detected in the included studies included beryllium, arsenic, cadmium, antimony, mercury, thallium, and bismuth, which were under 0.03 µg/g and were lower than the maximum limit level listed in the Chinese Pharmacopoeia \[[@B65-biomedicines-07-00060]\]. GFW is believed to be a safe herbal product as only a small number of minor gastrointestinal symptoms were reported as adverse effects: two studies reported adverse events, including diarrhea (*n* = 15) \[[@B15-biomedicines-07-00060]\] and abnormal feeling in the gastrointestinal tract (*n* = 2) \[[@B27-biomedicines-07-00060]\]. They were the main causes leading to drop out. Additionally, an in vivo study on Sprague-Dawley rats indicating that GFW was not carcinogenic after a continuous 24-month intervention \[[@B87-biomedicines-07-00060]\]. Results from another in vitro experiment \[[@B68-biomedicines-07-00060]\] on estrogen-dependent human breast cancer (MCF-7) cells showed that GFW at concentrations of 10.6--10.4 mg/mL did not activate the proliferation of MCF-7 cell, which suggested that GFW did not exhibit estrogen activity. Therefore, GFW might be a potential therapeutic option for MHFs in women who are undergoing breast cancer treatment.

4.4. Implications for Future Research {#sec4dot4-biomedicines-07-00060}
-------------------------------------

In total, 169 compounds from GFW and three potential target proteins/cytokine (estrogen beta receptor, IL-8, and CGRP receptor) were identified based on findings from the above-mentioned clinical and experimental studies. However, at this stage, a clear understanding of their interactions could not be obtained based on current literature. The bioactivities of the phytochemicals and their mechanisms of actions on MHF were not fully investigated. Although quality control is improving during the last two decades, evidenced by the increased quantitative index from one in the 2005 edition to two or three in the 2015 edition of the Chinese Pharmacopeia \[[@B17-biomedicines-07-00060]\], not all the herbal ingredients have a quantitative index. The clinical effects of CHM are often regarded as the result of the multi-targeting interaction of various phytochemical compounds. Thus, more research on the mechanism of actions of CHM on a condition at the molecular level (ligand-target interaction) and the therapeutic dose of the bioactive compounds are warranted.

5. Conclusions {#sec5-biomedicines-07-00060}
==============

This study identified 169 compounds from GFW pills, tablets, and capsules. Therapeutic effects, including frequency and severity of MHFs, peripheral blood flow, hormones, neurotransmitter, and cytokines, were not consistent across different study types. ESR2 with genetic variation, CGRP receptor, and IL-8 were identified to be related to the mechanisms of actions of GFW on MHFs. The differences in therapeutic effects could be potentially due to dose variations among clinical and experimental studies and ESR2 gene differences in rats and homo species. Further clinical and experimental studies, as well as biochemical investigation on the mechanisms of actions of GFW, are warranted. It is recommended that the dose-dependent effects and ESR2 expression at the participant recruitment stage are considered in future investigation.
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![Flowchart of study selection procedures of Guizhi Fuling Wan on menopausal hot flushes.](biomedicines-07-00060-g001){#biomedicines-07-00060-f001}

![Molecular structures of the 24 chemical constituents of Guizhi Fuling Wan. Note: C3: Benzol-β-gentiobioside, C6: Mandelic acid gentiobioside/isomer, D1: 4′-O-galloypaeoniflorin, D6: Benzoylpaeoniflorin sulfate, D10: Galloyglucose/isomer, D12: Galloylpaeoniflorin sulfonate, D13: Hexagalloyl glucose, D14: Isoxypaeoniflora, D19: Tetragalloy glucose, D20: Trigalloy glucose, E1: 3-hydroxypaeonol, E10: Mudanpioside E sulfonate, F1: 1-O-β-[d]{.smallcaps}-glucopyranosyl-paeonisuffrone, F2: 6-O-β-[d]{.smallcaps}-glucopyranosyl lactinolide, F7: Isomaltopaeoniflorin sulfonate, G4: 25-Hydroxypachymic acid, G5: 31-Hydroxyl-16-O-acetylpachymic acid, G10: 3-oxo-6,16α-dihydroxy-lanosta-7,9(11),24(31)-trien-21-oic acid, G12: 3β,16α-Dihydroxy-lanosta-7,9(11),24-trien-21-oic acid, G14: 6α-Hydroxydehydropachymic acid, G21: Pachymic acid methyl ester, H1: (2R)-\[(6-O-β-[d]{.smallcaps}-glucopyranosyl-β-[d]{.smallcaps}-glucopyranosyl) oxy\] (phenyl) ethanoic acid, H2: 2,5-dihydroxy-4-methylacetophenone, H15: Benzyl-β-[d]{.smallcaps}-glucopyranosyl-(1→6)-β-[d]{.smallcaps}-glucopyranoside.](biomedicines-07-00060-g002){#biomedicines-07-00060-f002}

![Quality assessment of included in vivo studies according to ARRIVE (Animal Research: Reporting of In Vivo Experiments) guideline.](biomedicines-07-00060-g003){#biomedicines-07-00060-f003}

![Therapeutic effects of Guizhi Fuling Wan on menopausal hot flushes across different types of studies. Notes: CGRP: calcitonin gene-related peptide; E~2~: estradiol; ESR: estrogen receptor; FSH: follicle-stimulating hormone; 1IL: interleukin; LH: luteinizing hormone; LL: two long alleles; MIP: macrophage inflammatory protein; MCP: serum monocyte chemotactic protein; RCT: randomized controlled trial.](biomedicines-07-00060-g004){#biomedicines-07-00060-f004}

biomedicines-07-00060-t001_Table 1

###### 

Characteristics and quality assessment of included studies of Guizhi Fuling Wan for menopausal hot flushes.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study Name                                                Setting (Country)                                    Sample Size; Age                    Diagnosis                                                                         Interventions                                                             Duration                                                      Outcomes Involved in this Review                                  Quality Assessment
  --------------------------------------------------------- ---------------------------------------------------- ----------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------
  **RCT**                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Plotnikoff et al. 2011 \[[@B15-biomedicines-07-00060]\]   University (US)                                      178; 45--58                         Post-menopausal                                                                   T1: GFW at 7.5 g/day (*n* = 62);\                                         12 weeks (12 weeks duration + 1-week placebo run-in period)   Frequency and severity of MHFs                                    L, L, L, L, L, H
                                                                                                                                                                                                                                       T2: GFW at 12.5 g/day (*n* = 57);\                                                                                                                                                                        
                                                                                                                                                                                                                                       C: Placebo (*n* = 59)                                                                                                                                                                                     

  Ushiroyama et al. 2005 \[[@B14-biomedicines-07-00060]\]   College (Japan)                                      140;\                               Post-menopausal                                                                   T: GFW 7.5 g/day (*n* = 70);\                                             1 month                                                       Blood flow in peripheral tissue                                   U, U, H, U, H, L
                                                                                                                 T: 53.1 ± 6.5;\                                                                                                       C: oral HT (Premarin R 0.625 mg/day + Provera R: 2.5 mg/day) (*n* = 70)                                                                                                                                   
                                                                                                                 C: 53.5 ± 6.2                                                                                                                                                                                                                                                                                                                   

  **Parallel Controlled Study**                                                                                                                                                                                                                                                                                                                                                                                                                  

  Yasui et al. 2011 \[[@B27-biomedicines-07-00060]\]        Outpatient clinic of a university hospital (Japan)   77;\                                Pre-menopausal, peri-menopausal, post-menopausal, and bilateral oophorectomized   T: GFW 7.5 g/day (*n* = 38);\                                             6 months                                                      The severity of MHFs, FSH, and E~2~ levels, IL-8, MCP-1, MIP-1β   L, L, L, L, M, S, L
                                                                                                                 T: 52 (39.3--58.7);\                                                                                                  C: No treatment (*n* = 39)                                                                                                                                                                                
                                                                                                                 C: 51 (43.4--57)                                                                                                                                                                                                                                                                                                                

  **Case Series**                                                                                                                                                                                                                                                                                                                                                                                                                                

  Chen and Shiraki 2003 \[[@B28-biomedicines-07-00060]\]    Clinic (Japan)                                       8; 53.59 ± 0.58                     Post-menopausal                                                                   GFW at 7.5 g/day (*n* = 8)                                                4 weeks                                                       Frequency of MHFs, plasma CGRP level                              High-quality (score = 8)

  Namiki et al. 2014 \[[@B29-biomedicines-07-00060]\]       Hospital and clinic of university (Japan)            39; 49.5 ± 4.69 (for 34 patients)   Post-menopausal (*n* = 18), 'not yet menopausal' (*n* = 21)                       GFW at 2.5 g, 3 times/day (*n* = 39)                                      12 weeks                                                      Severity of MHFs, FSH, and E~2~ levels                            High-quality (score = 10)

  Terauchi et al. 2010 \[[@B22-biomedicines-07-00060]\]     Hospital and clinic of university (Japan)            16; 51.1 ± 2.4                      Peri- and post-menopausal                                                         Education + GFW 7.5 g/day (*n* = 16)                                      144 ± 58 days                                                 Frequency of MHFs                                                 High-quality (score = 8)

  Terauchi et al. 2011 \[[@B23-biomedicines-07-00060]\]     Hospital and clinic of university (Japan)            30; 50.5 ± 5.2                      Peri- and post-menopausal                                                         Education + GFW 7.5 g/day (*n* = 30)                                      182 ± 76 days                                                 Frequency of MHFs                                                 High-quality (score = 7)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: C: control group; CGRP: calcitonin gene-related peptide; E~2~: estradiol; FSH: follicle-stimulating hormone; GFW: Guizhi Fuling Wan; H: high risk; MHFs: menopausal hot flushes; L: low risk; M: moderate risk; RCT: randomized controlled trial; S: serious risk; T: treatment group; U: unclear risk. Quality of RCTs was assessed Cochrane's risk of bias assessment tool \[[@B24-biomedicines-07-00060]\], quality of parallel controlled studies was evaluated by ROBINS-I ("Risk Of Bias In Non-randomised Studies - of Interventions") \[[@B25-biomedicines-07-00060]\], and case series were assessed according to the Instrument for Evaluating the Quality of case series in Chinese herbal medicine \[[@B26-biomedicines-07-00060]\].
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###### 

Chemical compounds from Guizhi Fuling Wan.

  ID      List of Chemical Compounds                                                                                    Form of GFW             Molecular Formula   Molecular Weight (g/mol)   PubChem CID/SID                                                                                                      Methods
  ------- ------------------------------------------------------------------------------------------------------------- ----------------------- ------------------- -------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **A**   **All ingredients (*n* = 1)**                                                                                                                                                                                                                                                                             
  A1      Sucrose/isomer (isomer only in Paeoniae radix)                                                                Capsule                 C12H22O11           342.297                    5988                                                                                                                 LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  **B**   **Cinnamomi Ramulus (*n* = 3)**                                                                                                                                                                                                                                                                           
  B1      Cinnamaldehyde                                                                                                Capsule, pill           C9H8O               132.162                    637511                                                                                                               HPLC \[[@B38-biomedicines-07-00060],[@B39-biomedicines-07-00060]\], SPE-HPLC \[[@B40-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\]
  B2      Cinnamic acid                                                                                                 Capsule, pill           C9H8O2              148.161                    444539                                                                                                               HPLC \[[@B38-biomedicines-07-00060],[@B39-biomedicines-07-00060]\], multiple chromatographic methods \[[@B42-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\], DGLC \[[@B44-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  B3      Protocatechuic acid                                                                                           Capsule                 C7H6O4              154.121                    72                                                                                                                   LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  **C**   **Persicae Semen (*n* = 12)**                                                                                                                                                                                                                                                                             
  C1      A-Linolenic acid                                                                                                                      C18H30O2            278.436                    5280934                                                                                                              HPLC \[[@B46-biomedicines-07-00060]\]
  C2      Amygdalin                                                                                                     Capsule, tablet         C20H27NO11          457.432                    656516                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC \[[@B47-biomedicines-07-00060],[@B48-biomedicines-07-00060],[@B49-biomedicines-07-00060],[@B50-biomedicines-07-00060],[@B51-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\], DGLC \[[@B44-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  C3      Benzol-β-gentiobioside                                                                                        Capsule                 C19H28O11           432.42                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C4      Betulinic acid                                                                                                Capsule                 C30H48O3            456.711                    64971                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C5      Linoleic acid                                                                                                 Capsule                 C18H32O2            280.452                    5280450                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B34-biomedicines-07-00060]\], HPLC \[[@B46-biomedicines-07-00060]\]
  C6      Mandelic acid gentiobioside/isomer                                                                            Capsule                 C20H28O13           476.43                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C7      Mandelic acid-β-[d]{.smallcaps}-glucopyranoside                                                               Capsule                 C14H18O8            314.29                     73229629                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C8      Oleic acid                                                                                                    Capsule                 C18H34O2            282.468                    445639                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC \[[@B46-biomedicines-07-00060]\]
  C9      Palmitic acid                                                                                                 Capsule                 C16H32O2            256.43                     985                                                                                                                  LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C10     Prunasin                                                                                                      Capsule                 C14H17NO6           295.291                    119033                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C11     Stearic acid                                                                                                  Capsule                 C18H36O2            284.484                    5281                                                                                                                 LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  C12     Trametenolic acid                                                                                             Capsule                 C30H48O3            456.711                    12309443                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  **D**   **Paeoniae Radix + Moutan Cortex (*n* = 20)**                                                                                                                                                                                                                                                             
  D1      4′-O-galloypaeoniflorin                                                                                       Capsule                 C30H32O15           632.56                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D2      4-hydroxybenzoic acid                                                                                         Capsule                 C7H6O3              138.122                    135                                                                                                                  LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  D3      4-O-galloylalbiflorin                                                                                         Capsule                 C30H32O15           632.571                    135397096                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D4      Albiflorin                                                                                                    Capsule                 C23H28O11           480.466                    51346141                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], RP-HPLC \[[@B52-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  D5      Benzoylpaeoniflorin/isomer                                                                                    Capsule                 C30H32O12           584.574                    21631106                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\]
  D6      Benzoylpaeoniflorin sulfate                                                                                   Capsule                 C30H32O14S          648.63                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D7      Desbenzoylalbiflorin/ isomer                                                                                  Capsule                 C16H24O10           376.358                    71452333                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D8      Digalloylglucose                                                                                              Capsule                 C20H20O14           484.366                    129628549                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D9      Gallic acid                                                                                                   Capsule                 C7H6O5              170.12                     370                                                                                                                  LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], RP-HPLC \[[@B52-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  D10     Galloyglucose/isomer                                                                                          Capsule                 C13H16O10           332.26                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D11     Galloyl paeoniflorin                                                                                          Capsule                 C30H32O15           632.571                    494717                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\]
  D12     Galloylpaeoniflorin sulfonate                                                                                 Capsule                 C30H32O17S          696.63                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D13     Hexagalloyl glucose                                                                                           Capsule                 C48H36O30           1092.78                    NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D14     Isoxypaeoniflora                                                                                              Capsule                 C23H28O12           496.46                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D15     Methyl gallate                                                                                                Capsule                 C8H8O5              184.147                    7428                                                                                                                 LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D16     Methyl vanillate                                                                                              Capsule                 C9H10O4             182.175                    19844                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D17     Oxypaeoniflorin                                                                                               Capsule                 C23H28O12           496.465                    21631105                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  D18     Pentagalloylglucose                                                                                           Capsule                 C41H32O26           940.681                    65238                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\]
  D19     Tetragalloy glucose                                                                                           Capsule                 C34H28O22           788.57                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  D20     Trigalloy glucose                                                                                             Capsule                 C27H24O18           636.47                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  **E**   **Moutan Cortex (*n* = 20)**                                                                                                                                                                                                                                                                              
  E1      3-hydroxypaeonol                                                                                              Capsule                 C9H10O4             182.17                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E2      Apiopaeonoside                                                                                                Capsule                 C20H28O12           460.432                    127509                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E3      Benzoyloxypaeoniflorin                                                                                        Capsule                 C30H32O13           600.573                    21631107                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\]
  E4      Galloyloxypaeoniflorin                                                                                        Capsule                 C30H32O16           648.56                     3036133                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E5      Mudanpioside A                                                                                                                        C31H34O13           614.6                      21631101                                                                                                             Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\], HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\]
  E6      Mudanpioside B                                                                                                Capsule                 C31H34O14           630.599                    21631102                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E7      Mudanpioside C                                                                                                Capsule                 C30H32O13           600.573                    21631098                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\]
  E8      Mudanpioside D                                                                                                Capsule                 C24H30O12           510.492                    21631103                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E9      Mudanpioside E                                                                                                Capsule                 C24H30O13           526.491                    21631104                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E10     Mudanpioside E sulfonate                                                                                      Capsule                 C24H30O14S          574.55                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E11     Mudanpioside F                                                                                                Capsule                 C16H24O8            344.36                     21631108                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  E12     Mudanpioside H/ isomer                                                                                        Capsule                 C30H32O14           616.572                    71457654                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E13     Mudanpioside J                                                                                                Capsule                 C31H34O14           630.599                    21593828                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E14     Paeonol                                                                                                       Capsule, pill, tablet   C9H10O3             166.176                    11092                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC \[[@B38-biomedicines-07-00060],[@B39-biomedicines-07-00060],[@B47-biomedicines-07-00060],[@B50-biomedicines-07-00060],[@B51-biomedicines-07-00060]\], gas chromatography \[[@B56-biomedicines-07-00060]\], RP-HPLC \[[@B57-biomedicines-07-00060],[@B58-biomedicines-07-00060]\], SPE-HPLC \[[@B40-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\], DGLC \[[@B44-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  E15     Paeonolide                                                                                                    Capsule                 C20H28O12           460.432                    442923                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E16     Paeonoside                                                                                                    Capsule                 C15H20O8            328.317                    53384347                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E17     Suffruticoside A                                                                                              Capsule                 C27H32O16           612.537                    9986231                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E18     Suffruticoside B                                                                                              Capsule                 C27H32O16           612.537                    10258205                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E19     Suffruticoside C                                                                                              Capsule                 C27H32O16           612.537                    10258206                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  E20     Suffruticoside D                                                                                              Capsule                 C27H32O16           612.537                    5321547                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  **F**   **Paeoniae Radix (*n* = 10)**                                                                                                                                                                                                                                                                             
  F1      1-O-β-[d]{.smallcaps}-glucopyranosyl-paeonisuffrone                                                           Capsule                 C16H24O9            360.36                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F2      6-O-β-[d]{.smallcaps}-glucopyranosyl lactinolide                                                              Capsule                 C16H26O9            362.37                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F3      Albiflorin R1                                                                                                 Capsule                 C23H28O11           480.466                    5317181 (CID), 50163461(SID)                                                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  F4      Digallic acid                                                                                                 Capsule                 C14H10O9            322.225                    341                                                                                                                  LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F5      Ethyl gallate                                                                                                 Capsule                 C9H10O5             198.174                    13250                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  F6      Galloylsucrose/isomer                                                                                         Capsule                 C19H26O15           494.402                    129629059                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F7      Isomaltopaeoniflorin sulfonate                                                                                Capsule                 C29H38O18S          706.66                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F8      Oxypaeoniflorin sulfonate                                                                                     Capsule                 C23H28O14S          560.523                    71455848                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  F9      Paeoniflorin                                                                                                  Capsule, pill, tablet   C23H28O11           480.466                    442534                                                                                                               LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC \[[@B47-biomedicines-07-00060],[@B50-biomedicines-07-00060],[@B51-biomedicines-07-00060],[@B59-biomedicines-07-00060],[@B60-biomedicines-07-00060]\], RP-HPLC \[[@B52-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\], DGLC \[[@B44-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\]
  F10     Paeoniflorin sulfonate                                                                                        Capsule                 C23H28O14S          560.523                    101382399                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\]
  **G**   **Poria (*n* = 30)**                                                                                                                                                                                                                                                                                      
  G1      16α-Hydroxytrametenolic acid                                                                                  Capsule                 C30H48O4            472.71                     132285301                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G2      16α-Hydroxydehydrotrametenolic acid                                                                           Capsule                 C30H46O4            470.694                    10743008                                                                                                             UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G3      2,3,6-Trimethylbenzoic acid                                                                                   Capsule                 C10H12O2            164.204                    17314                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G4      25-Hydroxypachymic acid                                                                                       Capsule                 C33H52O6            544.76                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G5      31-Hydroxyl-16-O-acetylpachymic acid                                                                          Capsule                 C38H52O5            588.81                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G6      3-epidehydropachymic acid                                                                                     Capsule                 C33H50O5            526.758                    15226716                                                                                                             Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\], HPLC \[[@B62-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G7      3-Epidehydrotumulosic acid                                                                                    Capsule                 C31H48O4            484.721                    10005581                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G8      3-O-acetyl-16α hydroxytrametenolic acid                                                                       Capsule                 C32H50O5            514.747                    9958136                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G9      3-O-acetyl-16α-hydroxydehydrotrametenolic acid                                                                Capsule                 C32H48O5            512.731                    15226714                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G10     3-oxo-6,16α-dihydroxy-lanosta-7,9(11),24(31)-trien-21-oic acid                                                Capsule                 C30H44O5            484.67                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"}) (structure found in \[[@B63-biomedicines-07-00060]\])   UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G11     3-oxo-6,16α-dihydroxy-lanosta-8,24-diene-21-oic acid                                                          Capsule                 NF                  NF                         NF (structure not available)                                                                                         UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G12     3β,16α-Dihydroxy-lanosta-7,9(11),24-trien-21-oic acid                                                         Capsule                 C30H46O4            470.68                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G13     3β-O-p-Hydroxybenzoyl-dehydro tumulosic acid                                                                  Capsule                 C38H52O6            604.828                    5318155                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G14     6α -Hydroxydehydropachymic acid                                                                               Capsule                 C33H50O6            542.74                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G15     Dehydroeburicoic acid                                                                                         Capsule                 C31H48O3            468.722                    15250826                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G16     Dehydropachymic acid                                                                                          Capsule                 C33H50O5            526.758                    15226717                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], HPLC \[[@B62-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G17     Dehydrotrametenolic acid                                                                                      Capsule                 C32H48O3            480.733                    129539661                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G18     Dehydrotumulosic acid                                                                                         Capsule                 C31H48O4            484.721                    15225964                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\], HPLC \[[@B62-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G19     Eburicoic acid                                                                                                Capsule                 C31H50O3            470.738                    73402                                                                                                                LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G20     Pachymic acid                                                                                                 Capsule                 C33H52O5            528.774                    5484385                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], HPLC-MS/MS \[[@B45-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G21     Pachymic acid methyl ester                                                                                    Capsule                 C34H54O5            542.79                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G22     Polyporenic acid C                                                                                            Capsule                 C31H46O4            482.705                    9805290                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC-MS/MS \[[@B64-biomedicines-07-00060]\], chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\], HPLC \[[@B62-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  G23     Poricoic acid A                                                                                               Capsule                 C31H46O5            498.704                    5471851                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G24     Poricoic acid AE                                                                                              Capsule                 C33H50O5            526.758                    102480392                                                                                                            LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G25     Poricoic acid AM                                                                                              Capsule                 C32H48O5            512.731                    46882717                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G26     Poricoic acid B                                                                                               Capsule                 C30H44O5            484.677                    5471852                                                                                                              LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G27     Poricoic acid BM                                                                                              Capsule                 C31H46O5            498.704                    15225967                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G28     Poricoic acid C                                                                                               Capsule                 C31H46O4            482.705                    16757534                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G29     Poricoic acid DM                                                                                              Capsule                 C32H48O6            528.73                     44424830                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\]
  G30     Tumulosic acid                                                                                                Capsule                 C31H50O4            486.737                    12314446                                                                                                             LC-MS/UPLC-ESI-Q-TOF-MS \[[@B37-biomedicines-07-00060]\], UPLC/Q-TOF-MS \[[@B61-biomedicines-07-00060]\]
  **H**   **Unclarified (*n* = 44)**                                                                                                                                                                                                                                                                                
  H1      (2R)-\[(6-O-β-[d]{.smallcaps}-glucopyranosyl-β-[d]{.smallcaps}-glucopyranosyl) oxy\] (phenyl) ethanoic acid   Capsule                 C20H28O13           475\. 145                  NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         HPLC-ESI-Q-TOF/MS \[[@B43-biomedicines-07-00060]\]
  H2      2,5-dihydroxy-4-methylacetophenone                                                                            Capsule                 C9H10O3             166.174                    NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  H3      4-o-methylbenzoylpaeoniflorin                                                                                 Capsule                 C31H34O12           598.601                    46883517                                                                                                             Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H4      4-o-methylgalloylpaeoniflorin                                                                                 Capsule                 C31H34O15           646.598                    46883518                                                                                                             Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H5      Adenosine                                                                                                     Capsule                 C10H13N5O4          267.245                    60961                                                                                                                Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H6      Affinoside                                                                                                    Capsule                 C20H28O12           460.432                    11972427                                                                                                             Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  H7      Alanine                                                                                                       Capsule                 C3H7NO2             89.094                     5950                                                                                                                 Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H8      A-Amyrin acetate                                                                                              Capsule                 C32H52O2            468.766                    92842                                                                                                                Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H9      A-D-Glucose                                                                                                   Capsule                 C6H12O6             180.156                    79025                                                                                                                Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B56-biomedicines-07-00060]\]
  H10     Apigenin                                                                                                      Capsule                 C15H10O5            270.24                     5280443                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H11     Arginine                                                                                                      Capsule                 C6H14N4O2           174.204                    6322                                                                                                                 Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B56-biomedicines-07-00060]\]
  H12     Astragalin                                                                                                    Capsule                 C21H20O11           448.38                     5282102                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H13     Benzoic acid                                                                                                  Capsule                 C7H6O2              122.123                    243                                                                                                                  HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\]
  H14     Benzoylpaeoniflorin                                                                                           Capsule                 C30H32O12           584.574                    21631106                                                                                                             HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\], UPLC \[[@B41-biomedicines-07-00060]\]
  H15     Benzyl-β-D-glucopyranosyl-(1→6)-β-D-glucopyranoside                                                           Capsule                 C18H26O10           402.39                     NF ([Figure 2](#biomedicines-07-00060-f002){ref-type="fig"})                                                         Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  H16     Β-Amyrin acetate                                                                                              Capsule                 C32H52O2            468.766                    92156                                                                                                                Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H17     Caffeic acid                                                                                                  Capsule                 C9H8O4              180.159                    689043                                                                                                               Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H18     Campesterol                                                                                                   Capsule                 C28H48O             400.691                    173183                                                                                                               Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H19     Catechin                                                                                                      Capsule                 C15H14O6            290.271                    9064                                                                                                                 Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H20     Cinnamyl alcohol                                                                                              Capsule                 C9H10O              134.178                    5315892                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H21     Coumarin                                                                                                      Capsule                 C9H6O2              146.145                    323                                                                                                                  Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H22     Epicatechin                                                                                                   Capsule                 C15H14O6            290.271                    72276                                                                                                                Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H23     Ergosta-4, 6, 8 (14), 22-tetraen-3-one                                                                        Capsule                 C28H40O             392.627                    6441416                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H24     Ergosterol                                                                                                    Capsule                 C28H44O             396.659                    444679                                                                                                               Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H25     Galactitol                                                                                                    Capsule                 C6H14O6             182.172                    11850                                                                                                                Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H26     Guanosine                                                                                                     Capsule                 C10H13N5O5          283.244                    6802                                                                                                                 Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H27     Heneicosanoic acid                                                                                            Capsule                 C21H42O2            326.565                    16898                                                                                                                Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H28     Hyperoside                                                                                                    Capsule                 C21H20O12           464.379                    5281643                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H29     Isomaltopaeoniflorin                                                                                          Capsule                 C29H38O16           642.607                    101001429                                                                                                            Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H30     Kaemferol                                                                                                     Capsule                 C15H10O6            286.239                    5280863                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H31     Leucine                                                                                                       Capsule                 C6H13NO2            131.175                    6106                                                                                                                 Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H32     O-β-D-Gentiobiosyl-[d]{.smallcaps}-(−)-mandelamide                                                            Capsule                 C20H29NO12          498\. 158                  181802                                                                                                               HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\]
  H33     Paeonidanin A                                                                                                 Capsule                 C31H34O12           598.601                    44253993                                                                                                             Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H34     Paeonidanin B                                                                                                 Capsule                 C31H34O15           646.598                    102417825                                                                                                            Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H35     Paeoniflorin B                                                                                                Capsule                 C36H42O17           746.715                    71452334                                                                                                             Chromatography on silica gel, Sephdex LH-20 columns and prep-HPLC-NMR \[[@B53-biomedicines-07-00060]\]
  H36     P-Coumaric acid                                                                                               Capsule                 C9H8O3              164.16                     637542                                                                                                               Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  H37     Proline                                                                                                       Capsule                 C5H9NO2             115.132                    145742                                                                                                               Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H38     Quercetin                                                                                                     Capsule                 C15H10O7            302.238                    5280343                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H39     Syringaresinol                                                                                                Capsule                 C22H26O8            418.442                    443023                                                                                                               Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H40     Syringic acid                                                                                                 Capsule                 C9H10O5             198.174                    10742                                                                                                                Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\], HPLC-ESI-QTOF/MS \[[@B43-biomedicines-07-00060]\]
  H41     Trans-2-Methoxycinnamic acid                                                                                  Capsule                 C10H10O3            178.187                    734154                                                                                                               Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  H42     Trehalose                                                                                                     Capsule                 C12H22O11           342.297                    7427                                                                                                                 Chromatography on silica gel, Sephdex LH-20 columns, D-101 macroporous resin column, and reverse RP-18 column and HPLC-NMR/MS \[[@B55-biomedicines-07-00060]\]
  H43     Umbelliferone                                                                                                 Capsule                 C9H6O3              162.144                    5281426                                                                                                              Chromatography on silica gel and polydextran gel columns and prep-HPLC-NMR/MS \[[@B54-biomedicines-07-00060]\]
  H44     Vanillic acid                                                                                                 Capsule                 C8H8O4              168.148                    8468                                                                                                                 Multiple chromatographic methods \[[@B42-biomedicines-07-00060]\]
  **J**   **Inorganic Elements (*n* = 29)**                                                                                                                                                                                                                                                                         
  J1      Aluminum                                                                                                      Capsule                 Al                  26.982                     5359268                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J2      Arsenic                                                                                                       Capsule                 As                  74.922                     5359596                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J3      Boron                                                                                                         Capsule                 B                   10.81                      5462311                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J4      Barium                                                                                                        Capsule                 Ba                  137.327                    5355457                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J5      Beryllium                                                                                                     Capsule                 Be                  9.012                      5460467                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J6      Bismuth                                                                                                       Capsule                 Bi                  208.98                     5359367                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J7      Calcium                                                                                                       Capsule                 Ca                  40.078                     5460341                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J8      Cadmium                                                                                                       Capsule                 Cd                  112.414                    23973                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J9      Cobalt                                                                                                        Capsule                 Co                  58.933                     104730                                                                                                               ICP-MS \[[@B65-biomedicines-07-00060]\]
  J10     Chromium                                                                                                      Capsule                 Cr                  51.996                     23976                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J11     Copper                                                                                                        Capsule                 Cu                  63.546                     23978                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J12     Iron                                                                                                          Capsule                 Fe                  55.845                     23925                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J13     Gallium                                                                                                       Capsule                 Ga                  69.723                     5360835                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J14     Mercury                                                                                                       Capsule                 Hg                  200.592                    23931                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J15     Lithium                                                                                                       Capsule                 Li                  6.94                       3028194                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J16     Magnesium                                                                                                     Capsule                 Mg                  24.305                     5462224                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J17     Manganese                                                                                                     Capsule                 Mn                  54.938                     23930                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J18     Molybdenum                                                                                                    Capsule                 Mo                  95.95                      23932                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J19     Sodium                                                                                                        Capsule                 Na                  22.99                      5360545                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J20     Nickel                                                                                                        Capsule                 Ni                  58.693                     935                                                                                                                  ICP-MS \[[@B65-biomedicines-07-00060]\]
  J21     Lead                                                                                                          Capsule                 Pb                  207.2                      5352425                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J22     Antimony                                                                                                      Capsule                 Sb                  121.76                     5354495                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J23     Selenium                                                                                                      Capsule                 Se                  78.971                     6326970                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J24     Tin                                                                                                           Capsule                 Sn                  118.71                     5352426                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J25     Strontium                                                                                                     Capsule                 Sr                  87.62                      5359327                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J26     Titanium                                                                                                      Capsule                 Ti                  47.867                     23963                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J27     Thallium                                                                                                      Capsule                 Tl                  204.38                     5359464                                                                                                              ICP-MS \[[@B65-biomedicines-07-00060]\]
  J28     Vanadium                                                                                                      Capsule                 V                   50.941                     23990                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]
  J29     Zinc                                                                                                          Capsule                 Zn                  65.38                      23994                                                                                                                ICP-MS \[[@B65-biomedicines-07-00060]\]

Notes: CID: compound identification number; DGLC: dual gradient liquid chromatography; ESI: electrospray ionization; ICP: inductively coupled plasma; LC: liquid chromatography; MS: mass spectrometry; NF: Not found; NMR: nuclear magnetic resonance spectroscopy; Q: quadrupole; RP: reverse phase; SID: substance identification number; SPE: solid-phase extraction; TOF: time of flight; UPLC: ultra performance liquid chromatography. Corresponding molecular structures refer to PubChem and [Figure 2](#biomedicines-07-00060-f002){ref-type="fig"}.
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###### 

Characteristics of in vivo studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID                                                  Language; Location                                                             Model                                                            Inducer                                                                                                        Age (week)   Weight (g)   Experiments   Sample Size        Interventions (Daily Dose, Administration)                                        Duration (days)   Included Outcome Measure and Results
  --------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------ ------------ ------------- ------------------ --------------------------------------------------------------------------------- ----------------- ----------------------------------------------
  Noguchi et al., 2003 a \[[@B66-biomedicines-07-00060]\]   English, Japan                                                                 Sprague-Dawley rats                                              OVX, capsaicin (1 mg/kg, i.p.) injection                                                                       10           200--250     1             32 (8/8/8/8)       1\. E~2~ (0.010 mg/kg, s.c.);\                                                    7                 CGRP concentrations in plasma ↑ (restore)
                                                                                                                                                                                                                                                                                                                                                                                      2. GFW (1000mg/kg, p.o.);\                                                                          
                                                                                                                                                                                                                                                                                                                                                                                      3. Distilled water (10 mL/kg, p.o.) to OVX rats;\                                                   
                                                                                                                                                                                                                                                                                                                                                                                      4. Distilled water (10 mL/kg, p.o.) to sham-operated rats.                                          

  OVX                                                       2                                                                              27 (7/7/7/7)                                                     CGRP concentrations in the spinal cord and dorsal root ganglia (no sig)                                                                                                                                                                                                       

  3                                                         20 (5/5/5/5)                                                                   CGRP mRNA levels in dorsal root ganglia (no sig)                                                                                                                                                                                                                                                                                               

  Noguchi et al., 2003 b \[[@B67-biomedicines-07-00060]\]   English, Japan                                                                 Sprague-Dawley rats                                              OVX                                                                                                            10           200--250     4             NS                 1\. GFW (100, 300, or 1000 mg/10 mL per kg, p.o., *n* = 7 or 8 in each group);\   7                 CGRP-induced elevation of skin temperature ↓
                                                                                                                                                                                                                                                                                                                                                                                      2. E~2~ (0.010 mg/mL per kg, s.c., *n* = 7);\                                                       
                                                                                                                                                                                                                                                                                                                                                                                      3. Distilled water (10 mg/kg, p.o., *n* = 8) to OVX rats;\                                          
                                                                                                                                                                                                                                                                                                                                                                                      4. GFW (1000 mg/10 mL per kg, p.o., *n* = 8) to sham-operated rats.                                 

  5                                                         45 (11/13/12/9)                                                                1\. GFW (1000 mg/10 mL per kg, p.o.);\                           CGRP-induced relaxation of Prostaglandin F2α-induced vasoconstriction in isolated mesenteric vascular beds ↓                                                                                                                                                                  
                                                                                                                                           2. E~2~ (0.010 mg/mL per kg, s.c.);\                                                                                                                                                                                                                                                                                                           
                                                                                                                                           3. Distilled water (10 mL/kg, p.o.) to OVX rats;\                                                                                                                                                                                                                                                                                              
                                                                                                                                           4. Distilled water (10 mL/kg, p.o.) to sham-operated rats.                                                                                                                                                                                                                                                                                     

  6                                                         32 (8/8/8/8)                                                                   125I-CGRP binding in isolated mesenteric arteries ↓                                                                                                                                                                                                                                                                                            

  7                                                         38 (10/9/10/9)                                                                 Plasma concentration of CGRP ↑                                                                                                                                                                                                                                                                                                                 

  8                                                         29 (7/7/8/7)                                                                   Plasma concentration of E~2~ (no sig); uterine weight (no sig)                                                                                                                                                                                                                                                                                 

  Noguchi et al., 2005 \[[@B68-biomedicines-07-00060]\]     English, Japan                                                                 Sprague-Dawley rats                                              GnRH analog Leupline (1 mg/kg) injection                                                                       9            200--240     9             36 (6/6/5/7/7/5)   1\. GFW (100 mg/kg, p.o.);\                                                       14                CGRP-induced elevation of skin temperature ↓
                                                                                                                                                                                                                                                                                                                                                                                      2. GFW (300 mg/kg, p.o.);\                                                                          
                                                                                                                                                                                                                                                                                                                                                                                      3. GFW (1,000 mg/kg, p.o.);\                                                                        
                                                                                                                                                                                                                                                                                                                                                                                      4. E~2~ (0.010 mg/kg, s.c.);\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                      5. Distilled water (10 mL/kg, p.o.) to injected rats;\                                              
                                                                                                                                                                                                                                                                                                                                                                                      6. Distilled water (10 mL/kg, p.o.) to sham-injected rats.                                          

  52 (13/13/13/13)                                          1\. GFW (1000 mg/kg, p.o.);\                                                   Plasma concentration of CGRP ↑                                                                                                                                                                                                                                                                                                                 
                                                            2. E~2~ (0.010 mg/kg, s.c.);\                                                                                                                                                                                                                                                                                                                                                                                                 
                                                            3. Distilled water (10 mL/kg, p.o.) to injected rats;\                                                                                                                                                                                                                                                                                                                                                                        
                                                            4. Distilled water (10 mL/kg, p.o.) to sham-injected rats.                                                                                                                                                                                                                                                                                                                                                                    

  28 (8/7/7/6)                                              Pituitary LH and FSH, plasma E~2~ and weights of uterus and ovaries (no sig)                                                                                                                                                                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: ↑: increased; ↓: decreased; CGRP: calcitonin gene-related peptide; E~2~: estradiol; FSH: follicle-stimulating hormone; GFW: Guizhi Fuling Wan; GnRH: gonadotropin-releasing hormone; i.p.: intraperitoneal injection; LH: luteinizing hormone; NS: not specified; OVX: ovariectomized; p.o.: oral administration; s.c.: subcutaneous injection; sig: significance.
